<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fexinidazole (United States: Not commercially available; refer to 'Product Availability' field): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fexinidazole (United States: Not commercially available; refer to 'Product Availability' field): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fexinidazole (United States: Not commercially available; refer to 'Product Availability' field): Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="132112" href="/d/html/132112.html" rel="external">see "Fexinidazole (United States: Not commercially available; refer to 'Product Availability' field): Drug information"</a> and <a class="drug drug_patient" data-topicid="132240" href="/d/html/132240.html" rel="external">see "Fexinidazole (United States: Not commercially available; refer to 'Product Availability' field): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F55993037"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiprotozoal, Nitroimidazole</span>;</li>
<li>
<span class="list-set-name">Antitrypanosomal</span></li></ul></div>
<div class="block dop drugH1Div" id="F56078541"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ee28489b-658b-4896-a20b-f26ecc0baff1">African trypanosomiasis, first-stage or second-stage disease, caused by <i>Trypanosoma brucei gambiense</i></span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>African trypanosomiasis (sleeping sickness), first-stage (hemolymphatic) or second-stage (with CNS involvement) disease, caused by <i>Trypanosoma brucei gambiense</i>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Patients with severe second-stage infection (cerebrospinal fluid WBC &gt;100 cells/mm<sup>3</sup>) should not be treated with fexinidazole if other treatment options (eg, nifurtimox-eflornithine combination therapy) are available.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents, weighing ≥20 kg:</p>
<p style="text-indent:-2em;margin-left:6em;">20 to &lt;35 kg: Oral: Initial: 1,200 mg once daily for 4 days, followed by a maintenance dose of 600 mg once daily for 6 days to complete a 10-day course.</p>
<p style="text-indent:-2em;margin-left:6em;">≥35 kg: Oral: Initial: 1,800 mg once daily for 4 days, followed by a maintenance dose of 1,200 mg once daily for 6 days to complete a 10-day course.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F56078543"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥6 years and Adolescents, weighing ≥20 kg:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Avoid use (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F56078544"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥6 years and Adolescents, weighing ≥20 kg: Mild to severe impairment: Use is contraindicated.</p></div>
<div class="block doa drugH1Div" id="F56092153"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="132112" href="/d/html/132112.html" rel="external">see "Fexinidazole (United States: Not commercially available; refer to 'Product Availability' field): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c262b8e5-58f1-4d0e-9360-24628e70889b">Human African trypanosomiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Human African trypanosomiasis: Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">20 to &lt;35 kg: 1.2 g once daily for 4 days; followed by 600 mg once daily for 6 days.</p>
<p style="text-indent:-2em;margin-left:4em;">≥35 kg: 1.8 g once daily for 4 days; followed by 1.2 g once daily for 6 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed dose: </i>If a dose is missed (ie, not taken on the assigned day), normal dosing should resume the following day until the full course (10 days) is complete (WHO 2019; manufacturer's labeling). If a dose is missed during days 1 to 4 and &gt;1 day has passed, restart treatment course. If a dose is missed during days 5 to 10, ensure that ≥3 doses (out of the 6 doses of the maintenance phase) are correctly taken; while not ideal, a minimum of 7 doses taken correctly (complete loading dose phase [days 1 to 4] plus ≥3 doses during the maintenance phase [days 5 to 10]) can be considered acceptable. If a second dose is missed, consider alternative treatment (WHO 2019).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F56092155"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Avoid use (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F56092156"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use is contraindicated.</p></div>
<div class="block arsc drugH1Div" id="F56552524"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Neuropsychiatric effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Neuropsychiatric effects, including <b>agitation</b>, <b>anxiety</b>, <b>abnormal behavior</b>, <b>depression</b>, <b>suicidal ideation</b>, <b>nightmares</b>, <b>hallucinations</b>, <b>personality changes</b>, <b>headache</b>, <b>insomnia</b>, and <b>tremor </b>have been observed during fexinidazole therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factor</i>s:</p>
<p style="text-indent:-2em;margin-left:6em;">• History of psychiatric disorders</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Psychotic reactions: Concomitant use with disulfiram or disulfiram use within the past 2 weeks</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">QT interval prolongation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole <b>prolonged QT interval on ECG</b> in a concentration-dependent manner (average increase of 19 msec in the QTcF interval).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced QTc prolongation/torsades de pointes (TdP) (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Structural heart disease (eg, history of myocardial infarction or heart failure with reduced ejection fraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic defects of cardiac ion channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of drug-induced TdP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Congenital long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Baseline QTc interval prolongation (eg, &gt;500 msec) or lengthening of the QTc by ≥60 msec (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Electrolyte disturbances (eg, hypocalcemia, hypokalemia, hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Loop diuretic use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Sepsis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent administration of multiple medications (≥2) that prolong the QT interval or medications with drug interactions that increase serum concentrations of QT-prolonging medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F56013864"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adolescents and adults unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypocalcemia (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Decreased appetite (21%), dyspepsia (13%), nausea (26%), vomiting (28%; pediatric patients: 20%, adult patients: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (19%), headache (35%)<span class="lexi-table-link-container"> (<a aria-label="Headache table link" class="lexi-table-link" data-table-id="lexi-content-headache" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-headache')">table 1</a>)</span><span class="table-link" style="display:none;">Headache</span>, insomnia (28%)<span class="lexi-table-link-container"> (<a aria-label="Insomnia table link" class="lexi-table-link" data-table-id="lexi-content-insomnia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-insomnia')">table 2</a>)</span><span class="table-link" style="display:none;">Insomnia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Headache" frame="border" id="lexi-content-headache" rules="all">
<caption style="text-align:center;">
<b>Fexinidazole: Adverse Reaction: Headache</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Fexinidazole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Nifurtimox-Eflornithine Combination Therapy)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Fexinidazole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Nifurtimox-Eflornithine Combination Therapy)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">35%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Second stage, meningoencephalitic human African trypanosomiasis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">264</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">130</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Insomnia" frame="border" id="lexi-content-insomnia" rules="all">
<caption style="text-align:center;">
<b>Fexinidazole: Adverse Reaction: Insomnia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Fexinidazole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Nifurtimox-Eflornithine Combination Therapy)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Fexinidazole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Nifurtimox-Eflornithine Combination Therapy)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Second stage, meningoencephalitic human African trypanosomiasis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">264</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">130</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (23%), back pain (11%), tremor (22%)<span class="lexi-table-link-container"> (<a aria-label="Tremor table link" class="lexi-table-link" data-table-id="lexi-content-tremor" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-tremor')">table 3</a>)</span><span class="table-link" style="display:none;">Tremor</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Tremor" frame="border" id="lexi-content-tremor" rules="all">
<caption style="text-align:center;">
<b>Fexinidazole: Adverse Reaction: Tremor</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Fexinidazole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Nifurtimox-Eflornithine Combination Therapy)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Fexinidazole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Nifurtimox-Eflornithine Combination Therapy)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Second stage, meningoencephalitic human African trypanosomiasis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">264</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">130</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (9%), hypertension (5%), palpitations (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis (3%), pruritus (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash (5%), hypoalbuminemia (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (3%), constipation (5%), gastritis (3%), sialorrhea (6%), upper abdominal pain (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal behavior (3%)<span class="lexi-table-link-container"> (<a aria-label="Abnormal Behavior table link" class="lexi-table-link" data-table-id="lexi-content-abnormal-behavior" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-abnormal-behavior')">table 4</a>)</span><span class="table-link" style="display:none;">Abnormal Behavior</span>, abnormal gait (5%), agitation (4%)<span class="lexi-table-link-container"> (<a aria-label="Agitation table link" class="lexi-table-link" data-table-id="lexi-content-agitation" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-agitation')">table 5</a>)</span><span class="table-link" style="display:none;">Agitation</span>, anxiety (4%)<span class="lexi-table-link-container"> (<a aria-label="Anxiety table link" class="lexi-table-link" data-table-id="lexi-content-anxiety" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anxiety')">table 6</a>)</span><span class="table-link" style="display:none;">Anxiety</span>, depression (&lt;2%), extrapyramidal reaction (3%), feeling hot (10%), hallucination (&lt;2%), paresthesia (2%), personality changes (&lt;2%), psychotic symptoms (&lt;2%), suicidal ideation (&lt;2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Abnormal Behavior" frame="border" id="lexi-content-abnormal-behavior" rules="all">
<caption style="text-align:center;">
<b>Fexinidazole: Adverse Reaction: Abnormal Behavior</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Fexinidazole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Nifurtimox-Eflornithine Combination Therapy)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Fexinidazole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Nifurtimox-Eflornithine Combination Therapy)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Second stage, meningoencephalitic human African trypanosomiasis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">264</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">130</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Agitation" frame="border" id="lexi-content-agitation" rules="all">
<caption style="text-align:center;">
<b>Fexinidazole: Adverse Reaction: Agitation</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Fexinidazole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Nifurtimox-Eflornithine Combination Therapy)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Fexinidazole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Nifurtimox-Eflornithine Combination Therapy)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Second stage, meningoencephalitic human African trypanosomiasis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">264</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">130</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anxiety" frame="border" id="lexi-content-anxiety" rules="all">
<caption style="text-align:center;">
<b>Fexinidazole: Adverse Reaction: Anxiety</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Fexinidazole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Nifurtimox-Eflornithine Combination Therapy)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Fexinidazole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Nifurtimox-Eflornithine Combination Therapy)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Second stage, meningoencephalitic human African trypanosomiasis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">264</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">130</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle spasm (3%), neck pain (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Photophobia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (6%), dyspnea (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Prolonged QT interval on ECG</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Nightmares</p></div>
<div class="block coi drugH1Div" id="F55992853"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to fexinidazole, other nitroimidazole derivatives (eg, metronidazole, tinidazole), or any component of the formulation; hepatic impairment.</p></div>
<div class="block war drugH1Div" id="F56092138"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Neutropenia: Neutropenia has been reported in patients receiving fexinidazole, particularly in patients with a baseline ANC &lt;5,000/mm<sup>3</sup>. Avoid concomitant use of medications that may cause neutropenia and monitor leukocyte count periodically.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Avoid use in patients with severe impairment (eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>).</p></div>
<div class="block prod-avail drugH1Div" id="F53795569"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Product is not commercially available in the United States; contact Sanofi regarding supply and distribution at https://www.sanofi.us or 1-800-981-2491.</p></div>
<div class="block accres drugH1Div" id="F56092134"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;">Product is not commercially available in the United States; contact Sanofi regarding supply and distribution at https://www.sanofi.us or 1-800-981-2491.</p></div>
<div class="block admp drugH1Div" id="F56078545"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Swallow tablets whole; do <b>not</b> break or crush. Administer during or immediately after the main meal of the day (within 30 minutes of the meal). A meal should consist of ≥250 mL of solid food; liquid food is not enough for adequate absorption (WHO 2019). If a first event of vomiting occurs &lt;2 hours after the administration of fexinidazole, do not administer an additional dose; continue with the next scheduled dose the following day (consider use of an antiemetic), and extend treatment 1 day longer. If vomiting occurs &gt;2 hours after fexinidazole administration, the dose is assumed to be sufficiently absorbed. If a second event of vomiting occurs after administration of any other dose, consider an alternative regimen (WHO 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Missed doses:</b> If a dose is missed (ie, not taken on the assigned day), normal dosing should resume the following day until the full course (10 days) is complete (WHO 2019; manufacturer's labeling). If a dose is missed during days 1 to 4 and &gt;1 day has passed, restart treatment course. If a dose is missed during days 5 to 10, ensure that ≥3 doses (out of the 6 doses of the maintenance phase) are correctly taken; while not ideal, a minimum of 7 doses taken correctly (complete loading dose phase [days 1 to 4] plus ≥3 doses during the maintenance phase [days 5 to 10]) can be considered acceptable. If a second dose is missed, consider alternative treatment (WHO 2019).</p></div>
<div class="block adm drugH1Div" id="F56092157"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer during or immediately after the main meal of the day, within 30 minutes of that meal. A meal should consist of at least 250 mL of <b>solid</b> food; liquid food is not enough for adequate absorption (WHO 2019). Swallow tablet whole (do not break or crush). If a first event of vomiting occurs &lt;2 hours after the administration of fexinidazole, do <b>not</b> administer an additional dose; continue with the next scheduled dose the following day (consider use of an antiemetic), and extend treatment 1 day longer. If vomiting occurs &gt;2 hours after fexinidazole administration, the dose is assumed to be sufficiently absorbed. If a second event of vomiting occurs after administration of any other dose, consider an alternative regimen (WHO 2019).</p></div>
<div class="block sts drugH1Div" id="F56092141"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store below 30°C (86°F). Protect from light and moisture.</p></div>
<div class="block usep drugH1Div" id="F55993051"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to <i>Trypanosoma brucei gambiense</i> (FDA approved in ages ≥6 years and weighing ≥20 kg and adults). <b>Note:</b> Due to the decreased efficacy observed in patients with severe second-stage <i>T. brucei gambiense</i> disease (cerebrospinal fluid WBC &gt;100 cells/mm<sup>3</sup>), fexinidazole should only be used in these patients if there are no other available treatment options.</p></div>
<div class="block cyt drugH1Div" id="F53848829"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (moderate), CYP2C19 (moderate)</p></div>
<div class="block dri drugH1Div" id="F53848826"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agomelatine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Agomelatine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Fexinidazole. A disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: CYP1A2 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Anagrelide. CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Anagrelide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belzutifan: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Belzutifan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the arrhythmogenic effect of Fexinidazole.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivaracetam: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Brivaracetam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromazepam: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Bromazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caffeine and Caffeine Containing Products: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Caffeine and Caffeine Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carisoprodol: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Carisoprodol. CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Carisoprodol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Chloroquine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: Fexinidazole may enhance the QTc-prolonging effect of Citalopram. Fexinidazole may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with fexinidazole, which is a moderate CYP2C19 inhibitor. Monitor for citalopram toxicity (eg, serotonin syndrome), QTc prolongation, and arrhythmias (including torsades de pointes).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloBAZam: CYP2C19 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of CloBAZam. CYP2C19 Inhibitors (Moderate) may increase the serum concentration of CloBAZam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Clofazimine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of ClomiPRAMINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Fexinidazole may enhance the QTc-prolonging effect of CloZAPine. Fexinidazole may increase the serum concentration of CloZAPine.  Management: Monitor for increased clozapine toxicities, including QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2B6 Substrates (High risk with Inducers): Fexinidazole may decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers).  Management: Avoid concomitant use of fexinidazole and CYP2B6 substrates when possible. If combined, monitor for reduced efficacy of the CYP2B6 substrate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May increase serum concentrations of the active metabolite(s) of Fexinidazole.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May increase serum concentrations of the active metabolite(s) of Fexinidazole.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May decrease serum concentrations of the active metabolite(s) of Fexinidazole. Management: Avoid use of fexinidazole and moderate CYP3A4 inhibitors when possible. If combined, monitor for reduced fexinidazole efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May decrease serum concentrations of the active metabolite(s) of Fexinidazole. Management: Avoid use of fexinidazole and strong CYP3A4 inhibitors when possible. If combined, monitor for reduced fexinidazole efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Substrates (High risk with Inhibitors): Fexinidazole may increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: Fexinidazole may enhance the QTc-prolonging effect of Dabrafenib. Dabrafenib may decrease the serum concentration of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexlansoprazole: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Dexlansoprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disulfiram: Fexinidazole may enhance the adverse/toxic effect of Disulfiram. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: Fexinidazole may enhance the QTc-prolonging effect of Encorafenib. Encorafenib may increase serum concentrations of the active metabolite(s) of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: Fexinidazole may enhance the QTc-prolonging effect of Escitalopram. Fexinidazole may increase the serum concentration of Escitalopram.  Management: Monitor for increased escitalopram toxicities (including increased QTc prolongation and serotonin syndrome) if combined with fexinidazole. Consider limiting the escitalopram dose to 10 mg daily when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fezolinetant: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Fezolinetant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: May enhance the myelosuppressive effect of Fexinidazole. Fexinidazole may enhance the QTc-prolonging effect of Fluorouracil Products.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gadobenate Dimeglumine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Gadobenate Dimeglumine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Haloperidol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lansoprazole: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Lansoprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Lofexidine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MATE1/2-K Substrates (Clinically Relevant with Inhibitors): Fexinidazole may increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors).  Management: Avoid use of fexinidazole with MATE1/2-K substrates when possible. If combined, monitor for increased MATE1/2-K substrate toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Mavacamten. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Melatonin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Moclobemide: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Moclobemide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Myelosuppressive Agents: May enhance the myelosuppressive effect of Fexinidazole.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OAT1/3 Substrates (Clinically Relevant): Fexinidazole may increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).  Management: Avoid use of fexinidazole with OAT1/3 substrates when possible. If combined, monitor for increased OAT1/3 substrate toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OCT2 Substrates (Clinically Relevant with Inhibitors): Fexinidazole may increase the serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors).  Management: Avoid use of fexinidazole with OCT2 substrates when possible. If combined, monitor for increased OCT2 substrate toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Fexinidazole may enhance the QTc-prolonging effect of OLANZapine. Fexinidazole may increase the serum concentration of OLANZapine.  Management: Monitor for increased olanzapine toxicities, including QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omeprazole: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Omeprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Ondansetron.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Pentamidine (Systemic).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pentoxifylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Piperaquine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: Avoid concomitant use of pirfenidone and moderate CYP1A2 inhibitors whenever possible. If combined, decrease the pirfenidone dose to 1,602 mg per day (534 mg three times daily) and monitor for increased pirfenidone toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probucol: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Probucol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Proguanil: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Proguanil. CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Proguanil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propofol: May enhance the arrhythmogenic effect of Fexinidazole. Propofol may enhance the QTc-prolonging effect of Fexinidazole.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): Fexinidazole may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): May enhance the QTc-prolonging effect of Fexinidazole. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): May enhance the QTc-prolonging effect of Fexinidazole. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Class IC Antiarrhythmics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of Fexinidazole. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): Fexinidazole may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of Fexinidazole. QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may decrease serum concentrations of the active metabolite(s) of Fexinidazole. Management: Consider alternatives to this combination. If combined, monitor for QT interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QT prolongation may be at even higher risk. Also monitor for reduced fexinidazole efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk): Fexinidazole may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk). QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk) may increase the serum concentration of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of Fexinidazole. QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may decrease serum concentrations of the active metabolite(s) of Fexinidazole. Management: Consider alternatives to this combination. If combined, monitor for QT interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QT prolongation may be at even higher risk. Also monitor for reduced fexinidazole efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rasagiline: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Rasagiline.  Management: Limit rasagiline dose to 0.5 mg once daily in patients taking moderate CYP1A2 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPivacaine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of ROPivacaine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Tasimelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Theophylline Derivatives.  Management: Consider avoidance of this combination. If coadministration is necessary, monitor for increased theophylline serum concentrations and toxicities when combined. Theophylline dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F56092140"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Following administration with food, the AUC of fexinidazole and its active metabolites was approximately 4- to 5-fold higher compared to the fasted state. Management: Administer during or immediately after the main meal of the day.</p></div>
<div class="block dic drugH1Div" id="F56092150"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Food: Take during or immediately after the main meal of the day.</p>
<p style="text-indent:-2em;margin-left:2em;">Ethanol: Avoid use of ethanol during treatment and for at least 48 hours after therapy discontinuation.</p></div>
<div class="block pri drugH1Div" id="F56092136"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were observed in animal reproduction studies with doses that were also maternally toxic.</p>
<p style="text-indent:0em;margin-top:2em;">Treatment of human African trypanosomiasis during pregnancy is recommended. Fexinidazole can be given after the first trimester to reduce the risk of fetal transmission of the disease, and to prevent maternal death in patients with moderate or severe disease (WHO 2019).</p></div>
<div class="block mopp drugH1Div" id="F56078548"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">LFTs and electrolytes (baseline and during treatment); CBC with differential; monitor for neuropsychiatric adverse effects including agitation, anxiety, abnormal behavior, depression, nightmares, hallucination, mood and personality changes, and suicidal ideation.</p></div>
<div class="block pha drugH1Div" id="F56092142"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Fexinidazole is a nitroimidazole derivative that is thought to be trypanocidal via bioactivation by parasite nitroreductase enzymes to generate reactive amines and damage DNA and proteins.</p></div>
<div class="block phk drugH1Div" id="F56092143"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid; administration with food increases AUC 4- to 5-fold relative to administration in fasted state.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 3,222 ± 1,199 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Fexinidazole: 98%; fexinidazole sulfoxide: 41%; fexinidazole sulfone: 57%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP-450; fexinidazole is extensively metabolized to active metabolites fexinidazole sulfoxide and fexinidazole sulfone.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Fexinidazole: 15 ± 6 hours; fexinidazole sulfoxide: 16 ± 6 hours; fexinidazole sulfone: 23 ± 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;3.2%; as metabolites).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Fexinidazole [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexinidazole-united-states-not-commercially-available-refer-to-product-availability-field-pediatric-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexinidazole-united-states-not-commercially-available-refer-to-product-availability-field-pediatric-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23716032">
<a name="23716032"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexinidazole-united-states-not-commercially-available-refer-to-product-availability-field-pediatric-drug-information/abstract-text/23716032/pubmed" id="23716032" target="_blank">23716032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24803473">
<a name="24803473"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2014;7(3):381-390. doi:10.1161/CIRCOUTCOMES.113.000651<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexinidazole-united-states-not-commercially-available-refer-to-product-availability-field-pediatric-drug-information/abstract-text/24803473/pubmed" id="24803473" target="_blank">24803473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31449367">
<a name="31449367"></a>World Health Organization (WHO). WHO interim guidelines for the treatment of gambiense human African trypanosomiasis. https://apps.who.int/iris/bitstream/handle/10665/326178/9789241550567-eng.pdf. Published 2019. Accessed August 10, 2021.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fexinidazole-united-states-not-commercially-available-refer-to-product-availability-field-pediatric-drug-information/abstract-text/31449367/pubmed" id="31449367" target="_blank">31449367</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 132113 Version 35.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
